Figure S24 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Year: 2026
Type: other
Abstract: Figure S24. µPET/CT imaging and biodistribution with [89Zr]DFO*-YS5-MMAE in 22Rv1 tumor-bearing mice. (A). Axial, coronal, and maximum intensity projection (MIP) PET/CT images of mice (M1–M4) at 24, 48, 96, and 168 hours post-injection of [89Zr]DFO*-YS5-MMAE. The images show sustained and specific uptake in 22Rv1 tumors over time. Color scale represents % injected dose per gram of tissue (%ID/g), indicating consistent tumor retention up to 7 days post-injection. (B) Biodistribution of [89Zr]DFO-YS5-MMAE in 22Rv1 tumor-bearing mice at 168 hours post-injection (n=4).
Authors: Anil P. Bidkar, Scott Bidlingmaier, Anju Wadhwa, Ellis Mayne, Athira Raveendran, Shubhankar Naik, Cheng Xue, Megha Basak, Kondapa Naidu Bobba, Bonell Patiño-Escobar, Nancy Greenland, Juan Antonio Camara Serrano, Veronica Steri, Jonathan Chou, Arun Wiita, Jiang He, David M. Wilson, Rahul Aggarwal, Henry F. VanBrocklin, Youngho Seo, Bin Liu, Robert R. Flavell
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7164996942